期刊
ARCHIVES OF PHARMACAL RESEARCH
卷 43, 期 11, 页码 1144-1161出版社
PHARMACEUTICAL SOC KOREA
DOI: 10.1007/s12272-020-01281-8
关键词
Ubiquitin– proteasome system (UPS); E3 ligase; Deubiquitinating enzymes (DUBs); Proteasome; Cancer; Small molecule inhibitors
资金
- National Research Foundation of Korea (NRF) - Korean government (MSIP) [2020R1A4A4079494, 2019R1A2C2004052]
- National Research Foundation of Korea [2019R1A2C2004052, 2020R1A4A4079494] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
The ubiquitin-proteasome system (UPS) plays an important role in the cellular processes for protein quality control and homeostasis. Dysregulation of the UPS has been implicated in numerous diseases, including cancer. Indeed, components of UPS are frequently mutated or abnormally expressed in various cancers. Since Bortezomib, a proteasome inhibitor, received FDA approval for the treatment of multiple myeloma and mantle cell lymphoma, increasing numbers of researchers have been seeking drugs targeting the UPS as a cancer therapeutic strategy. Here, we introduce the essential component of UPS, including ubiquitinating enzymes, deubiquitinating enzymes and 26S proteasome, and we summarize their targets and mechanisms that are crucial for tumorigenesis. In addition, we briefly discuss some UPS inhibitors, which are currently in clinical trials as cancer therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据